LipoScience Announces Agreement With ARUP Clinical Laboratories For Placement Of Vantera® Clinical Analyzer

LipoScience, Inc., LPDX a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced an agreement to place the Vantera® Clinical Analyzer within ARUP Laboratories' facilities. The agreement will make NMR lipoprotein testing on the Vantera Clinical Analyzer accessible to customers of ARUP Laboratories later this year. The Vantera Clinical Analyzer can identify and quantify concentrations of lipoproteins using NMR spectroscopy and proprietary signal processing algorithms. Such analysis provides physicians and patients with a detailed assessment of cardiovascular disease (CVD) risk from a single blood test that measures the concentration of low-density lipoprotein particles (LDL-P) and other lipoprotein information within a patient's blood sample. LDL-P is the first FDA-cleared assay on the Vantera Clinical Analyzer and a key component of LipoScience's NMR LipoProfile® test. To date, over 10 million NMR LipoProfile tests have been ordered to aid in CVD risk management. Adoption and decentralization of the Vantera Clinical Analyzer into clinical laboratories will ultimately provide widespread access to the NMR LipoProfile test, reduce sample processing turnaround time and provide value to physicians focused on delivering quality patient care and personalized management of cardiovascular disease. "Historically, LipoScience has processed all samples for the NMR LipoProfile test. We are excited to offer NMR lipoprotein testing and other NMR-based assays as the Vantera menu expands, directly through our laboratory," said Dr. Jerry Hussong, chief medical officer at ARUP. "Providing information on LDL-P, which has been shown to correlate with cardiovascular disease risk, supports our efforts to streamline patient management through timely provision of personalized information." "Having ARUP Laboratories place the Vantera Clinical Analyzer and offer the NMR LipoProfile test is a significant milestone as we drive toward regional access and widespread adoption of the test," said Peter Riefenhauser, vice president of marketing at LipoScience. "This placement is consistent with our vision of NMR diagnostics becoming a clinical standard of care for measuring lipoproteins and other small-molecule metabolites to advance patient care." About LipoScience, Inc. LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company's first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 10 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, Vantera®, has been cleared by the U.S. Food and Drug Administration (FDA). It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories. LipoScience is driving NMR diagnostics toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com. About ARUP Laboratories Founded in 1984, ARUP Laboratories is a leading national reference laboratory and a nonprofit enterprise of the University of Utah and its Department of Pathology. ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. ARUP serves clients across the United States, including many of the nation's top university teaching hospitals and children's hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and other government facilities, and major clinics. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical and Experimental Pathology®.